Results of complex treatment of patients with operable pancreatic head cancer using preoperative intra-arterial chemotherapy in combination with radiation therapy in multifractionation mode

The aim of this study was to assess the safety and efficacy of treating patients with operable pancreatic cancer after preoperative intra-arterial infusion of chemotherapy combined with conformal radiation therapy in a multi-fractionation mode. Patients (n = 40) were randomized into two groups: the main one – intra-arterial infusion of chemotherapy + radiation therapy + surgery (n = 20), and control – intra-arterial infusion of chemotherapy + surgery (n = 20). Neoadjuvant therapy consisted of intra-arterial infusion of chemotherapy (chemoembolization of a pancreatic head tumor with oxaliplatin 85 mg/m2) followed by intra-arterial chemo infusion with gemcitabine 1000 mg/m2. In the main group, radiation therapy was also carried out in two fractions per day, 2 Gy with an interval of 4–6 hours, 5 days a week, up to a total dose of 50 Gy. In the main group, the lower incidence of postoperative pancreatitis and the pancreatic fistulas were statistically confirmed, the incidence of grade 2 therapeutic pathomorphisis increased, as well as the median life expectancy.

1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World Journal of Oncology. 2019; 10 (1): 10–27. https://doi.org/10.14740/wjon1166

2. Ed. A. D. Kaprin, V. V. Starinsky, G. V. Petrova. The state of cancer care for the population of Russia in 2017. M.: MNIOI them. P. A. Herzen – a branch of National Medical Research Center of Radiology of the Ministry of Health of Russia, 2018. ill. 236 s.

3. Pokataev I. A., Gladkov O. A., Zagainov V. E., Kudashkin N. E., Lyadov V. K., Patyutko Yu.I. et al. Practical recommendations for drug treatment of pancreatic cancer. Malignant tumors 10.3s2–1 (2021): 487–501.

4. Ducreux M. et al. Haustermans k, Van Laethem JL, Conroy T, Aenold D: Cancer of the Pancreas: ESMO clinical practise guidelines. Annals of Oncology. 2015; (5): 56–68. https://doi.org/10.1093/annonc/mdv295

5. Tempero M. A. et al. Pancreatic Adenocarcinoma, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2021; 19 (4): 439–457. https://doi.org/10.6004/jnccn.2021.0017

6. Pan L., Fang J., Tong C. et al. Survival benefits of neoadjuvant chemo (radio) therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World journal of surgical oncology. 2020; 18 (1):1–13. https://doi.org/10.1186/s12957–019–1767–5

7. Han D., Gao F., Liu J. L. et al. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study. BMC cancer. 2021; 21 (1): 1–11. https://doi.org/10.1186/s12885–021–08288–4

8. Cloyd J. M. et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials. Journal of clinical medicine. 2020; 9 (4): 1129. https://doi.org/10.3390/jcm9041129

9. Seshacharyulu P. et al. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2017; 1868 (1): 69–92. https://doi.org/10.1016/j.bbcan.2017.02.003

10. Versteijne E. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. Journal of Clinical Oncology. 2020; 38 (16): 1763–1773. https://doi.org/10.1200/JCO.19.02274

11. Pusceddu S. et al. Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers. 2019; 11 (4): 484. https://doi.org/10.3390/cancers11040484

12. Jin C, Yao L, Long J, et al. Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin Med J (Engl). 2009; 122 (3): 284–290.

13. Davis JL, Pandalai PK, Ripley RT, Langan RC, Avital I. Expanding surgical treatment of pancreatic cancer: the role of regional chemotherapy. Pancreas. 2012; 41 (5): 678–684. https://doi.org/10.1097/MPA.0b013e318249955a

14. D. A. Granov et al. Evaluation of the safety of intra-arterial chemotherapy with gemcitabine and oxaliplatin in the combined treatment of adenocarcinoma of the pancreatic head. Annals of Surgical Hepatology. 2017; 22 (2): 54–59. https://doi.org/10.16931/1995–5464.2017254–59

15. Qiu B. et al. Transcatheter arterial infusion for pancreatic cancer: a 10-year National Cancer Center experience in 115 patients and literature review. Abdominal Radiology. 2019; 44 (8): 2801–2808. https://doi.org/10.1007/s00261–019–02022–2

16. Yan M., Sigurdson S., Greifer N., Kennedy T. A., Toh T. S., Lindsay P. E. et al. A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted Analysis. Cancers. 2021; 13 (12): 2895. https://doi.org/10.3390/cancers13122895

17. Coen JJ, Zhang P, Saylor PJ, et al. Bladder Preservation with Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. Journal Clinical Oncology. 2019; 37 (1): 44–51. https://doi.org/10.1200/JCO.18.00537

18. Brierley James D., Mary K. Gospodarowicz, and Christian Wittekind, eds. TNM classification of malignant tumours. John Wiley & Sons, 2017.

19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5 (6): 649–655.

20. Lushnikov E. F. (1993) Therapeutic pathomorphosis of tumors. In the book Pathological diagnosis of human tumors. Ed. ON THE. Kraevsky, A. V. Smolyannikova, D. S. Sarkisova M.: Medicine, 560 p.

21. Gerasimov A. N. Medical statistics. A. N. Gerasimov. Moscow: Medical Information Agency, 2007.475 p.

22. Kaplan EL., Meier P. Nonparametric estimation from incomplete observations. Journal of the American statistical association. 1958; 53 (282): 457–481.

23. Tsai S., Erickson B. A., Dua K., Ritch P. S., Tolat P., & Evans D. B. Evolution of the management of resectable pancreatic cancer. Journal of oncology practice. 2016; 12: 772–778. https://doi.org/10.1200/JOP.2016.015818

24. Kozlov A. V. et al. Arterial chemoembolization in patients with locally advanced pancreatic cancer. Bulletin of surgery named after I. I. Grekov. 2018; 177 (1): 31–36. https://doi.org/10.24884/0042–4625–2018–177–1–31–36

25. Korytova L. I. et al. Possibilities of conformal radiation therapy in the treatment of patients with locally advanced pancreatic cancer. Russian biotherapeutic journal. 2017; 16 (1): 44–45.

26. Peng JS, Wey J, Chalikonda S, Allende DS, Walsh RM, Morris-Stiff G. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2019; 18 (4): 373–378. https://doi.org/10.1016/j.hbpd.2019.05.007

27. Pavlovsky A. V. et al. Influence of perioperative intra-arterial selective chemotherapy on the period of recurrence of ductal adenocarcinoma of the pancreatic head after pancreatoduodenal resection. Annals of Surgical Hepatology. 2018; 23 (3): 14–22. https://doi.org/10.16931/1995–5464.2018314–22